Abstract: Esophageal cancer is one of the most common malignant tumors in China. Its early diagnosis rate is low, with most patients already in an advanced disease stage at the time of diagnosis; patient prognosis is poor; and 5-year survival rate is low. Radiotherapy plays an important role in treating esophageal cancer, and although radiotherapy techniques have greatly improved, they still do not significantly improve the survival rate and overall efficacy. Research on radiation dose is in the midst of bottleneck period, whereas chemotherapy, targeted therapy, and immunotherapy combined with radiotherapy are becoming the hotspots. This review summarizes research advamcement regarding radiotherapy and comprehensive treatment of esophageal and esophagogastric junction cancer at the 2020 ASCO annual meeting and recent years.